Tudor Investment Corp ET AL Sells 221,184 Shares of Progyny, Inc. $PGNY

Tudor Investment Corp ET AL lowered its stake in Progyny, Inc. (NASDAQ:PGNY) by 46.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 250,849 shares of the company’s stock after selling 221,184 shares during the quarter. Tudor Investment Corp ET AL owned 0.29% of Progyny worth $5,398,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in PGNY. Vanguard Group Inc. grew its holdings in shares of Progyny by 2.4% in the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after purchasing an additional 235,513 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in Progyny by 2.1% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,931,249 shares of the company’s stock valued at $41,560,000 after buying an additional 39,666 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in Progyny by 33.1% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock valued at $35,649,000 after buying an additional 412,395 shares during the period. Finally, Barclays PLC boosted its position in Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after buying an additional 696,447 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PGNY shares. Truist Financial decreased their price objective on shares of Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, March 2nd. Citigroup upgraded shares of Progyny to an “outperform” rating in a report on Tuesday, January 20th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Citizens Jmp upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a report on Tuesday, January 20th. Finally, KeyCorp lowered their price target on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $27.91.

Insider Buying and Selling at Progyny

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 7,455 shares of company stock worth $129,515 over the last ninety days. 9.40% of the stock is currently owned by company insiders.

Progyny Trading Up 0.2%

Shares of PGNY stock opened at $18.05 on Wednesday. Progyny, Inc. has a 12 month low of $16.75 and a 12 month high of $28.75. The stock has a market cap of $1.48 billion, a PE ratio of 27.77, a price-to-earnings-growth ratio of 1.04 and a beta of 1.01. The company’s fifty day moving average price is $21.05 and its 200-day moving average price is $22.47.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. During the same period last year, the business earned $0.42 EPS. Progyny’s quarterly revenue was up 6.7% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, sell-side analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.